Consensus IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
43.31 USD +1.88% Intraday chart for IDEAYA Biosciences, Inc. -3.35% +21.73%

Evolution of the average Target Price on IDEAYA Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4000b9.xQhpsOoegti4KEO_FJmz5O_KM3VFb23qfiKrlPoqqMI.lzkw0qBR9qn3YnTGUcvUrp66HjwIGDuvIU3M1plu3JGwZyTBq3bg7OpQKA~e55d4e6440e928c23658596210fc6e1e
Citigroup Raises IDEAYA Biosciences' Price Target to $60 From $40, Maintains Buy Rating MT
BTIG Starts Coverage on IDEAYA Biosciences With Buy Rating, $55 Price Target MT
RBC Raises Price Target on IDEAYA Biosciences to $53 From $43 on 'Clarity & Confidence on Daro's Potential,' Keeps Outperform Rating, Speculative Risk MT
Wedbush Raises IDEAYA Biosciences' PT to $52 From $46, Updates Model to Include Recent Financings; Keeps Outperform Rating MT
Goldman Sachs Adjusts Price Target on IDEAYA Biosciences to $53 From $36, Maintains Buy Rating MT
Wedbush Raises Price Target on IDEAYA Biosciences to $46 From $43, Maintains Outperform Rating MT
RBC Adjusts IDEAYA Biosciences' Price Target to $43 From $36, Keeps Outperform Rating MT
JPMorgan Raises IDEAYA Biosciences' Price Target to $35 From $32, Maintains Overweight Rating MT
RBC Raises Price Target on IDEAYA Biosciences to $36 From $32, Keeps Outperform Rating, Speculative Risk Qualifier MT
Wedbush Lifts Ideaya Biosciences' Price Target to $43 From $40 After Phase 1 Study of Novel PARG Inhibitor IDE16 Early Results, Keeps Outperform Rating MT
Goldman Sachs Adjusts IDEAYA Biosciences' Price Target to $37 From $31, Keeps Buy Rating MT
Wedbush Lifts Ideaya Biosciences' Price Target to $43 From $40, Keeps Outperform Rating MT
JPMorgan Chase Raises Price Target on IDEAYA Biosciences to $32 From $28, Maintains Overweight Rating MT
Oppenheimer Adjusts IDEAYA Biosciences Price Target to $35 From $30, Maintains Outperform Rating MT
RBC Raises Price Target on IDEAYA Biosciences to $32 From $30, Maintains Outperform Rating, Speculative Risk Qualifier MT
Wedbush Raises IDEAYA Biosciences' PT to $40 From $35 on Increased Confidence in IDE397/AMG 193 Combination, Keeps Outperform Rating MT
SVB Securities Initiates IDEAYA Biosciences With Outperform Rating, $33 Price Target MT
Wedbush Trims Foghorn Therapeutics Price Target to $13 From $14, Maintains Outperform Rating MT
Goldman Sachs Initiates IDEAYA Biosciences at Buy With $32 Price Target MT
Wedbush Adjusts Price Target on IDEAYA Biosciences to $35 From $30, Maintains Outperform Rating MT
Guggenheim Adjusts Price Target on IDEAYA Biosciences to $40 From $32, Maintains Buy Rating MT
Stifel Upgrades IDEAYA Biosciences to Buy From Hold, Adjusts Price Target to $24 From $18 MT
Berenberg Initiates IDEAYA Biosciences at Buy With $26 Price Target MT
IDEAYA Biosciences Initiated by RBC at Outperform With Speculative Risk, Price Target Set at $25 Amid Bullish View on Daro MT
Capital One Initiates IDEAYA Biosciences at Overweight Rating With $29 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
43.31 USD
Average target price
53.27 USD
Spread / Average Target
+23.00%
High Price Target
60 USD
Spread / Highest target
+38.54%
Low Price Target
50 USD
Spread / Lowest Target
+15.45%

Consensus detail

Consensus revision (last 18 months)

Analysts covering IDEAYA Biosciences, Inc.

Citigroup
BTIG
RBC Capital Markets
Wedbush
Goldman Sachs
JPMorgan Chase
Oppenheimer
SVB Securities LLC
Guggenheim
Stifel Nicolaus
Berenberg Bank
Capital One Securities
Baird
Roth Capital Partners
Barclays
J.P. Morgan Chase
HC Wainwright
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings